Se Hwan Yang

NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. Our lead drug candidate, NT-I7, is the only clinical-stage long acting rhIL-7, and is uniquely positioned to address unmet medical needs in Immuno-Oncology and Infectious Diseases such as COVID-19. IL-7 is a fundamental cytokine for lymphocyte development, survival, and memory development. Furthermore, NT-I7 has been shown clinically to have desired PK/PD and safety profiles, making it an ideal combination partner with T-cell targeted therapies as well as vaccines. NT-I7 is being studied in multiple clinical trials and many in collaboration with industry leaders in I-O, including Merck, BMS, and Roche for CPI combination trials. Follow us on Twitter @neoimmunetech